Literature DB >> 21147294

Post-treatment imaging appearances in head and neck cancer patients.

C Offiah1, E Hall.   

Abstract

Surgery and radiotherapy (with or without chemotherapy) for head and neck cancer can create a daunting array of radiological appearances post-treatment. The role of the radiologist lies not only in detecting recurrent neoplastic disease, but also identifying non-neoplastic changes that may account for clinical presentation and symptoms in this patient group. There are a number of non-neoplastic as well as neoplastic changes and disease entities that can present on surveillance imaging, such as primary resection and reconstructive surgical change, surgical neck dissection changes, radionecrosis, post-treatment denervation change, and radiotherapy-related secondary tumours. Some of these require conservative management, while others require more active treatment. Awareness and recognition of the imaging appearances of these post-treatment changes is therefore critical for the radiologist involved in the multidisciplinary care of the head and neck cancer patient.
Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21147294     DOI: 10.1016/j.crad.2010.09.004

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  14 in total

1.  Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: application of high b-value diffusion-weighted imaging.

Authors:  I Hwang; S H Choi; Y-J Kim; K G Kim; A L Lee; T J Yun; J-h Kim; C-H Sohn
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-27       Impact factor: 3.825

Review 2.  Imaging of Surgical Free Flaps in Head and Neck Reconstruction.

Authors:  J L McCarty; A S Corey; M W El-Deiry; H M Baddour; B M Cavazuti; P A Hudgins
Journal:  AJNR Am J Neuroradiol       Date:  2018-11-08       Impact factor: 3.825

3.  Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment.

Authors:  Matthew N DeSalvo
Journal:  J Radiol Case Rep       Date:  2012-07-01

Review 4.  Postoperative Imaging and Surveillance in Large Nerve Perineural Spread.

Authors:  Jennifer Sommerville; Mitesh Gandhi
Journal:  J Neurol Surg B Skull Base       Date:  2016-02-09

5.  PET/MRI and PET/CT in follow-up of head and neck cancer patients.

Authors:  Marcelo A Queiroz; Martin Hüllner; Felix Kuhn; Gerhardt Huber; Christian Meerwein; Spyros Kollias; Gustav von Schulthess; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-28       Impact factor: 9.236

Review 6.  Osteoradionecrosis of the skull base.

Authors:  John P Leonetti; Jeffrey R Weishaar; David Gannon; Grant A Harmon; Alec Block; Douglas E Anderson
Journal:  J Neurooncol       Date:  2020-05-11       Impact factor: 4.130

7.  Radionecrosis of the frontal lobe as a consequence of malignant ethmoid tumor management: incidence, diagnosis, risk factors, prevention and management.

Authors:  N Oker; P Lang; D Bresson; B George; J-P Guichard; M Wassef; E Sauvaget; S Froelich; R Kania; P Herman
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-16       Impact factor: 2.503

8.  Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer.

Authors:  Denys J Loeffelbein; Michael Souvatzoglou; Veronika Wankerl; Julia Dinges; Lucas M Ritschl; Thomas Mücke; Anja Pickhard; Matthias Eiber; Markus Schwaiger; Ambros J Beer
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

9.  Post-treatment appearances, pitfalls, and patterns of failure in head and neck cancer on FDG PET/CT imaging.

Authors:  Nilendu C Purandare; Ameya D Puranik; Sneha Shah; Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2014-07

10.  Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis.

Authors:  Guohua Shen; Shuang Hu; Bin Liu; Anren Kuang
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.